The production of PMPs that was attributed to in situ activation of platelets could release aPD-1 antibodies in a bioresponsive manner, further re-activating exhausted CD8+ T cells for enhanced anti-tumor efficacy. This evidence concerns the gene CD8A and neoplasm.